Purpose: Comprehensive genomic profiling (CGP) is of increasing value for patients with
metastatic castration-resistant prostate cancer (mCRPC). mCRPC tends to metastasize to …

Background: Real-time knowledge of the somatic genome can influence management of
patients with metastatic castration-resistant prostate cancer (mCRPC). While routine …

Background Metastatic prostate cancer is a clonally heterogeneous disease state
characterized by progressive somatic perturbations. The aim of this study was to identify cell …

Background Multiple treatments are available for metastatic castration-resistant prostate
cancer (mCRPC), including androgen receptor signaling inhibitors (ARSI) enzalutamide and …

Background Several systemic therapeutic options exist for metastatic castrate-sensitive
prostate cancer (mCSPC). Circulating tumor DNA (ctDNA) can molecularly profile metastatic …

Importance The molecular landscape underpinning response to the androgen receptor (AR)
antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer …

The genomic landscape of metastatic castration-resistant prostate cancer (mCRPC) differs
from that of the primary tumor and is dynamic during tumor progression. The real-time and …

Purpose: Not all patients with metastatic castration-resistant prostate cancer (mCRPC) have
sufficient tumor tissue available for multigene molecular testing. Furthermore, samples may …

The genomics of primary prostate cancer differ from those of metastatic castration-resistant
prostate cancer (mCRPC). We studied genomic aberrations in primary prostate cancer …

Purpose: Beyond enumeration, circulating tumor cells (CTCs) can provide genetic
information from metastatic cancer that may facilitate a greater understanding of tumor …